Printer Friendly

TARGET THERAPEUTICS TO BEGIN MARKETING ZEPHYR CATHETER; WILL RESPOND TO FDA ON GUGLIELMI DETACHABLE COIL

 FREMONT, Calif., July 8 /PRNewswire/ -- Target Therapeutics Inc. (NASDAQ: TGET) announced today that it will begin U.S. marketing of its Zephyr(TM) Flow-Assisted Infusion Catheter for treatment of certain vascular disorders, in particular arteriovenous malformations (AVMs). The announcement was made following receipt of a premarket notification (510(k)) from the U.S. Food and Drug Administration (FDA) for the Zephyr(TM) catheter.
 The Zephyr(TM) incorporates a highly flexible shaft material and patented design that allow interventional physicians to advance the micro-catheter rapidly through tortuous blood vessels using a flow- directed technique, while maintaining some torqueability to permit steering.
 "Flow-directed" refers to the use of blood flow to access a disease site, thereby eliminating the need for a guidewire to navigate the patient's vascular system and allowing physicians to access the site of disorders more efficiently. AVMs, for example, are aberrant interconnections of arteries and veins characterized by increased blood flow, and left untreated may rupture and cause hemorrhagic stroke. Treatment using the Zephyr(TM) catheter allows subsequent surgical removal of AVMs with significantly reduced blood loss and shortened surgical procedure time.
 "The Zephyr combines the speed of flow-directed access techniques with control and maneuverability," said Gary Bang, president and chief executive officer of Target. "With an estimated 4,000 AVMs currently treated each year in the U.S., we are pleased to provide another device for use in neurointerventional medicine." Target's sales force will begin marketing the Zephyr(TM) catheter immediately.
 Company to Respond to FDA Correspondence on Guglielmi Detachable Coil
 Target also announced that it is in the process of formulating a response to questions recently received from the FDA regarding the company's Guglielmi Detachable Coil (GDC), an investigational medical device intended for the treatment of cerebral aneurysms. The company believes that it can respond to these questions using existing data supplemented with results from minor additional in vitro laboratory tests.
 In November 1992 the company filed an application for a 510(k) clearance with the FDA. The GDC fills the space in the aneurysm -- balloon-like formations that protrude from weakened blood vessels and that may cause stroke when ruptured and left untreated -- promoting complete clotting and facilitating the eventual closing-off and stabilization of the aneurysm.
 Founded in 1985, Target Therapeutics Inc. develops, manufactures and markets specialized disposable micro-catheters, guidewires, micro-coils and angioplasty products. These therapeutic devices are used in minimally invasive non-surgical procedures to reach disease sites throughout the body via the circulatory system. Target's products allow highly targeted treatment of the diseased, ruptured or blocked vessels of the brain responsible for stroke, as well as other disease sites in the body that are accessible through small blood vessels.
 -0- 7/8/93
 /CONTACT: analysts, Larry Tannenbaum, vice president of finance and administration, chief financial officer, of Target Therapeutics, 510-440-7700; media, Bruce Voss of Edelman Public Relations, 415-433-5381, for Target Therapeutics/
 (TGET)


CO: Target Therapeutics Inc. ST: California IN: MTC SU: PDT

LH-TM -- SF003 -- 9326 07/08/93 08:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 8, 1993
Words:495
Previous Article:COSTCO WHOLESALE CORP. ADOPTS SHAREHOLDER RIGHTS PLAN
Next Article:SCIOS NOVA ANNOUNCES NEW VICE PRESIDENT OF PRODUCT DEVELOPMENT
Topics:


Related Articles
TARGET THERAPEUTICS ANNOUNCES FIRST QUARTER RESULTS
TARGET THERAPEUTICS ANNOUNCES GUGLIELMI DETACHABLE COIL DEVELOPMENT
TARGET THERAPEUTICS CFO UPDATES INVESTORS AT WESSELS, ARNOLD INVESTMENT CONFERENCE; REPORTS RECENT GDC DEVELOPMENTS, CITES INCREASING COMMUNITY...
TARGET THERAPEUTICS ANNOUNCES FISCAL 1994 RESULTS
TARGET THERAPEUTICS ANNOUNCES THIRD QUARTER RESULTS
TARGET THERAPEUTICS RECEIVES FDA CLEARANCE TO MARKET THE GUGLIELMI DETACHABLE COIL (GDC(TM)) FOR TREATMENT OF INTRACRANIAL ANEURYSMS
TARGET THERAPEUTICS ANNOUNCES ACQUISITION OF INTERVENTIONAL THERAPEUTICS CORPORATION
TARGET THERAPEUTICS ANNOUNCES COMPLETION OF ACQUISITION OF INTERVENTIONAL THERAPEUTICS CORPORATION
Target Therapeutics Receives Clearance to Market First Generation GDC(R) in Japan
Target Therapeutics Receives Final Clearance to Market GDC in Japan

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters